bluebird bio sells itself to Carlyle, SK Capital

Bluebird Bio to Be Acquired by Carlyle Group, SK Capital
Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.
Struggling bluebird bio to go private for less than $30m
Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a publicly traded company. The agreement comes after years of financial struggles,
Bluebird Bio sells itself to Carlyle, SK Capital for less than $30 million
Bluebird Bio announced it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30 million.
Bluebird Bio to be acquired by Carlyle, SK Capital for $3.00 per share
Bluebird Bio (BLUE) announced that it has entered into a definitive agreement to be acquired by funds managed by Carlyle (CG) and SK Capital
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
SOMERVILLE, Mass., February 21, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners,
Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch
Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ending its tumultuous journey in the public markets as it struggled with a severe cash crunch.
bluebird bio plunges after take-private deal with Carlyle and SK Capital
(NASDAQ:BLUE) lost ~37% in the premarket on Friday after the gene therapy developer announced its plans to become a privately held biotech as part of an M&A agreement with private equity firms Carlyle Group (NASDAQ:CG) and SK Capital Partners.
Gene therapy maker bluebird to go private in discounted deal amid cash crunch
Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle and SK Capital Partners at a discount, ending ...
Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
FiercePharma3h
Once valued at $10B, bluebird bio sold to private equity firms for $29M
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
BioPharma Dive2h
Bluebird, at risk of default, agrees to take-private deal
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...
Bluebird Bio trading halted, volatility trading pause
EST Bluebird Bio (BLUE) trading halted, volatility trading pauseDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are ...
Laguna Beach begins work on Bluebird Canyon fuel modification zone
Hand crews will work over the next year to form a new fuel modification zone in the Bluebird Canyon area of Laguna Beach, the ...
Hoodline20h
Shelby County Bluebird Club Seeks Volunteers to Sustain Conservation Work in Germantown
The Shelby County Bluebird Club seeks leadership volunteers to continue their critical role in conserving the local bluebird population, with roles like President and Treasurer unfilled.